GSK Looks To Cross PD-1 Gap And Leap To Next-Generation IO Backbone
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma provided an update of its immuno-oncology pipeline during an R&D day and announced a partnership to study its OX40 agonist antibody in combination with Merck’s PD-1 inhibitor Keytruda.